Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 35.5% from a year ago
Cash & equivalents stood at $78.06M at the end of Q1 FY2026, up 35.5% from a year earlier and up 48.3% from the prior quarter. Over 3 fiscal years it compounded at +19.1% a year.
Context
- Cash & equivalents amounted to 15.7% of total assets at the end of Q1 FY2026, down 3.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +35.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 52.65M USD
- Year-over-year change
- -7.3%
- 3-year CAGR
- +19.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.65M | -7.3% |
| FY2024 | 2024-12-31 | 56.81M | -19.0% |
| FY2023 | 2023-12-31 | 70.17M | +125.2% |
| FY2022 | 2022-12-31 | 31.16M | — |
Cash & Equivalents vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 cash & equivalents of $78.06M is the 7th highest of the 10 companies compared; the peer median is $263.76M.
- Its year-over-year change of +35.5% is the 6th highest of 10, against a peer median of +64.1%.
- Cash & equivalents amounts to 15.7% of total assets for RAPP, versus a peer median of 54.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $976.45M | +278.5% | +15.7% | 54.4% | |
| Sep 2026 | $361.85M | +142.0% | +79.7% | 27.6% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $320.68M | +2154.3% | +126.9% | 81.5% |
| Jun 2026 | $319.85M | +5.6% | +17.2% | 42.0% | |
| Mar 2026 | $263.76M | +64.1% | +54.0% | 95.5% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $147.07M | +15.9% | -8.8% | 95.6% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $78.06M | +35.5% | +19.1% | 15.7% |
| Mar 2026 | $55.71M | +11.1% | +19.1% | 13.3% | |
| Mar 2026 | $31.13M | +89.5% | -4.0% | 86.1% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $20.16M | -10.3% | +138.6% | 7.7% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $263.76M | +64.1% | +19.1% | 54.4% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.